These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17641441)

  • 21. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.
    Gutierrez AD; Sathyanarayana P; Konduru S; Ye Y; Birnbaum Y; Bajaj M
    Atherosclerosis; 2012 Jul; 223(1):204-8. PubMed ID: 22687642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
    Gastaldelli A; Casolaro A; Pettiti M; Nannipieri M; Ciociaro D; Frascerra S; Buzzigoli E; Baldi S; Mari A; Ferrannini E
    Clin Pharmacol Ther; 2007 Feb; 81(2):205-12. PubMed ID: 17259945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome.
    Kato T; Sawai Y; Kanayama H; Taguchi H; Terabayashi T; Taki F; Yamada K; Yamazaki Y; Hayakawa N; Suzuki A; Oda N; Katada N; Itoh M
    Exp Clin Endocrinol Diabetes; 2009 Nov; 117(10):593-9. PubMed ID: 19924605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
    Aso Y; Yamamoto R; Suetsugu M; Matsumoto S; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
    Diabet Med; 2007 Sep; 24(9):962-8. PubMed ID: 17509067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    van der Meer RW; Rijzewijk LJ; de Jong HW; Lamb HJ; Lubberink M; Romijn JA; Bax JJ; de Roos A; Kamp O; Paulus WJ; Heine RJ; Lammertsma AA; Smit JW; Diamant M
    Circulation; 2009 Apr; 119(15):2069-77. PubMed ID: 19349323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].
    Yu Y; Li Y; Fan J; Wang Y; Yu H; Wang C; Liao Z; Gao H; Zhao W
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):117-20. PubMed ID: 15600200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
    Suzuki H; Sakamoto M; Hayashi T; Iuchi H; Ohashi K; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
    Cardiovasc Diabetol; 2013 May; 12():71. PubMed ID: 23635096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes.
    Aso Y; Hara K; Ozeki N; Yatsuka C; Nakano T; Matsumoto S; Suetsugu M; Nakamachi T; Takebayashi K; Haruki K; Inukai T
    Diabetes Res Clin Pract; 2009 Aug; 85(2):147-52. PubMed ID: 19545925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
    Abe M; Okada K; Maruyama T; Maruyama N; Soma M; Matsumoto K
    Expert Opin Pharmacother; 2010 Jul; 11(10):1611-20. PubMed ID: 20540652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.